ITRM20030572A1 - Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. - Google Patents

Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.

Info

Publication number
ITRM20030572A1
ITRM20030572A1 IT000572A ITRM20030572A ITRM20030572A1 IT RM20030572 A1 ITRM20030572 A1 IT RM20030572A1 IT 000572 A IT000572 A IT 000572A IT RM20030572 A ITRM20030572 A IT RM20030572A IT RM20030572 A1 ITRM20030572 A1 IT RM20030572A1
Authority
IT
Italy
Prior art keywords
prune
metastases
tumors
experienced
prevention
Prior art date
Application number
IT000572A
Other languages
English (en)
Inventor
Massimo Zollo
Original Assignee
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Telethon filed Critical Fond Telethon
Priority to IT000572A priority Critical patent/ITRM20030572A1/it
Priority to ES04806854T priority patent/ES2389550T3/es
Priority to CA002549291A priority patent/CA2549291A1/en
Priority to JP2006543723A priority patent/JP2007513940A/ja
Priority to CN2004800368658A priority patent/CN1897951B/zh
Priority to EP04806854A priority patent/EP1699460B1/en
Priority to PCT/IT2004/000689 priority patent/WO2005056043A2/en
Priority to AU2004296643A priority patent/AU2004296643B2/en
Priority to US10/582,115 priority patent/US20090118171A1/en
Publication of ITRM20030572A1 publication Critical patent/ITRM20030572A1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
IT000572A 2003-12-11 2003-12-11 Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. ITRM20030572A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT000572A ITRM20030572A1 (it) 2003-12-11 2003-12-11 Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.
ES04806854T ES2389550T3 (es) 2003-12-11 2004-12-10 Uso de inhibidores enzimáticos de h-PRUNE para la prevención y tratamiento de las metástasis de tumores que sobreexpresan h-PRUNE
CA002549291A CA2549291A1 (en) 2003-12-11 2004-12-10 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
JP2006543723A JP2007513940A (ja) 2003-12-11 2004-12-10 ｈ−ＰＲＵＮＥを過剰発現する腫瘍の転移を予防及び治療するためのｈ−ＰＲＵＮＥの酵素阻害剤の使用
CN2004800368658A CN1897951B (zh) 2003-12-11 2004-12-10 h-PRUNE的酶抑制剂在制备预防和治疗过度表达h-PRUNE的肿瘤转移的药物中的应用
EP04806854A EP1699460B1 (en) 2003-12-11 2004-12-10 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
PCT/IT2004/000689 WO2005056043A2 (en) 2003-12-11 2004-12-10 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
AU2004296643A AU2004296643B2 (en) 2003-12-11 2004-12-10 Use of enzymatic inhibitors of h-PRUNE for the prevention and treatment of the metastases of tumours overexpressing h-PRUNE
US10/582,115 US20090118171A1 (en) 2003-12-11 2004-12-10 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000572A ITRM20030572A1 (it) 2003-12-11 2003-12-11 Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.

Publications (1)

Publication Number Publication Date
ITRM20030572A1 true ITRM20030572A1 (it) 2005-06-12

Family

ID=34674585

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000572A ITRM20030572A1 (it) 2003-12-11 2003-12-11 Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.

Country Status (9)

Country Link
US (1) US20090118171A1 (it)
EP (1) EP1699460B1 (it)
JP (1) JP2007513940A (it)
CN (1) CN1897951B (it)
AU (1) AU2004296643B2 (it)
CA (1) CA2549291A1 (it)
ES (1) ES2389550T3 (it)
IT (1) ITRM20030572A1 (it)
WO (1) WO2005056043A2 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20060037A1 (it) 2006-01-25 2007-07-26 Bio Flag S R L Inibitori della migrazione cellulare mediata dal complesso tra h-prune e gsk-3 relativi usi nella terapia antitumorale
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
US9801853B2 (en) 2010-04-06 2017-10-31 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2014045310A1 (en) * 2012-09-19 2014-03-27 Massimo Zollo Pyrimido[5,4-d]pyrimidine or pyrimidine derivatives compounds and uses thereof in the treatment of cancer
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
CN108624674B (zh) * 2018-03-30 2020-11-24 青岛泱深生物医药有限公司 Krt73作为分子靶标在帕金森诊治中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
AU2002359242A1 (en) * 2001-08-17 2003-04-22 Incyte Genomics, Inc. Intracellular signaling molecules

Also Published As

Publication number Publication date
ES2389550T3 (es) 2012-10-29
EP1699460B1 (en) 2012-06-13
EP1699460A2 (en) 2006-09-13
CA2549291A1 (en) 2005-06-23
US20090118171A1 (en) 2009-05-07
WO2005056043A3 (en) 2005-07-14
AU2004296643A1 (en) 2005-06-23
WO2005056043A2 (en) 2005-06-23
AU2004296643B2 (en) 2010-09-09
CN1897951B (zh) 2011-09-28
JP2007513940A (ja) 2007-05-31
CN1897951A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
ATE445614T1 (de) Phosphatidylinositol 3-kinase inhibitoren
ITMI991608A0 (it) Sonda elettrochirurgica per il trattamento di tumori mediante radiofre quenza
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
ATE505471T1 (de) Azaindol-kinaseinhibitoren
IL229160B (en) Rapamycin derivatives for treatment of solid tumors
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
ZA200309738B (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same.
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
ATE416171T1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
IS6968A (is) Nýir týrósínkínasa tálmar
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
PT1425270E (pt) Metodos para preparacao de inibidores de cetp.
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
IS6918A (is) Meðferð erfiðra æxla með notkun epóþílon afleiða
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
ITRM20030572A1 (it) Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
EP1583528A4 (en) NF-KB INHIBITORS AND USES THEREOF
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks